December 2024 - Page 3 of 12

$ASH 2024 | Dr. Hu Zhou: Exploring the Efficacy and Safety of a Novel SYK Inhibitor in Patients with Relapsed/Refractory ITP$

ASH 2024 | Dr. Hu Zhou: Exploring the Efficacy and Safety of a Novel SYK Inhibitor in Patients with Relapsed/Refractory ITP

By El Bachir MOURABIT 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, drawing global experts and scholars to discuss the latest advancements in hematology. In recent years, increasing insights into the pathogenesis of immune thrombocytopenia (ITP) have paved the way for innovative treatment strategies, among which SYK inhibitors have garnered significant attention due to their unique mechanisms of action. At this year’s ASH conference, Dr. Hu Zhou from Henan Cancer Hospital shared his team’s latest findings (711) on this front, offering fresh perspectives for future therapeutic strategies. Hematology Frontier invited Dr. Zhou for an in-depth discussion on his study and its clinical significance.

$ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma$

ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma

By Mourabit Halima 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450), offering novel perspectives and important insights into immunotherapy combinations for relapsed/refractory lymphoma. Hematology Frontier invited Dr. Cai to share the clinical significance and key findings of her team’s research.

ASH 2024 | Dr. Wei Xu: Redefining CNS Involvement Evaluation and Prophylactic Strategies with CSF-ctDNA Testing

By Mourabit Halima 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this prestigious event, Dr. Wei Xu’s team from The First Affiliated Hospital of Nanjing Medical University presented their groundbreaking research titled Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort. This study, selected for oral presentation (O576), not only deepens our understanding of CNS involvement in DLBCL but also offers innovative perspectives for clinical management and treatment strategies. Hematology Frontier invited Dr. Xu to share insights into the significance of CSF-ctDNA testing, its potential role in future DLBCL clinical practice, and its far-reaching impact on patient treatment strategies.

ASH 2024 | Dr. Yang Liang: New Insights and Future Perspectives on Clonal Hematopoiesis

By Yin, Jiale 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this year’s conference, Dr. Yang Liang’s team from Sun Yat-sen University Cancer Center presented groundbreaking research on the mechanisms of clonal hematopoiesis (O192). The findings revealed a novel connection between DNMT3A mutations and immune microenvironment dysregulation, offering a fresh perspective on the origins and progression of clonal hematopoiesis. Hematology Frontier invited Dr. Liang for an in-depth discussion on the clinical significance of this research and its potential future applications.

ASH 2024 | Dr. Haiwen Huang: Insights into New Strategies for Non-Hodgkin Lymphoma (NHL)—CMOP±R Regimen, Combined Therapies, and Transplant Options

By Mourabit Halima 2024.12.25

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions (P1676, P3113, P4442). Hematology Frontier invited Professor Huang to share their insights and the clinical implications of these studies directly from the ASH venue.

SABCS 2024 | Dr. Biyun Wang: Real-World Comparison of CDK4/6 Inhibitor + Endocrine Therapy vs. Chemotherapy for First-Line HR+/HER2- MBC Treatment

By Mourabit Halima 2024.12.25

In the treatment landscape of HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become a widely used first-line treatment. However, patients with symptomatic visceral metastases often opt for chemotherapy (CT). While some prospective studies suggest that CDK4/6i + ET may yield better outcomes even in patients with visceral metastases, no studies have explored these strategies in real-world settings.

SABCS 2024 | Dr. Biyun Wang: Latest Clinical Trial Results of GQ1005 in HER2-Positive Metastatic Breast Cancer Patients

By Mourabit Halima 2024.12.24

The 47th San Antonio Breast Cancer Symposium (SABCS) is in full swing in San Antonio, USA, showcasing cutting-edge research from around the world. On December 12 (Central Time), during the “Poster Spotlight – Session 8: Novel HER2 Therapeutics”, Dr. Biyun Wang and her team from Fudan University Shanghai Cancer Center presented their groundbreaking findings on GQ1005, a highly promising HER2 antibody-drug conjugate (ADC). The study’s evaluation of GQ1005’s efficacy and safety in HER2-positive metastatic breast cancer (MBC) patients drew significant attention, leading to vibrant discussions among experts. Dr. Wang provides an in-depth interpretation of this important research.

SABCS 2024 | Dr. Biyun Wang: Pharmacokinetics and Preliminary Efficacy of GQ1001 Combined with Pyrotinib in HER2+ MBC Patients Previously Treated

By Peng Longmei 2024.12.24

The treatment of HER2-positive breast cancer remains a focal point in clinical research. At the 2024 San Antonio Breast Cancer Symposium (SABCS), a phase 1b study led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center presented promising results (Abstract No. P5-05-02). This study explored the pharmacokinetics and preliminary efficacy of a novel HER2 antibody-drug conjugate (ADC), GQ1001, combined with pyrotinib in patients with HER2-positive metastatic breast cancer (MBC) who had undergone prior treatments. Here, we provide an overview of this groundbreaking research.

Dr. Nanlin Li: Efficacy and Safety of Envafolimab Combined with Pyrotinib and Nab-Paclitaxel in Neoadjuvant Therapy for HER2-Positive Breast Cancer

By Peng Geng 2024.12.24

At the 2024 San Antonio Breast Cancer Symposium (SABCS), one of the world’s most prestigious events in breast cancer research, Chinese scholars once again demonstrated their exceptional expertise and innovative spirit in the field of breast cancer treatment. A groundbreaking study led by Dr. Nanlin Li and his team from Xijing Hospital of the Air Force Medical University brings renewed hope to breast cancer patients in China and offers fresh strategies to the global breast cancer research community. This study focuses on precision therapy for breast cancer, exploring the efficacy and safety of envafolimab combined with pyrotinib and nab-paclitaxel in the neoadjuvant treatment of HER2-positive breast cancer. Below, we provide a detailed introduction to the research.

Dr. Yunjian Liu: The Emerging Value of ctDNA Monitoring in Neoadjuvant Therapy for Breast Cancer—Predicting Treatment Response and Recurrence Risk

By Mourabit Halima 2024.12.24

From December 10 to 13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in the field of breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advancements, and technological innovations from the past year.Among the many noteworthy contributions, a study by Dr. Yunjian Liu's team from The Fourth Hospital of Hebei Medical University stood out. Their research focused on the prognostic value of ctDNA monitoring in breast cancer patients undergoing neoadjuvant therapy and was presented as a poster (Abstract No. P3-05-22). The study highlights how personalized ctDNA testing can dynamically monitor minimal residual disease (MRD), predict treatment efficacy and recurrence risk, and provide valuable insights for clinical decision-making. Oncology Frontier interviewed Professor Liu onsite for an in-depth discussion.